Abstracts tagged "Disease Activity"

Abstract Number: 1065 • 2017 ACR/ARHP Annual Meeting
Mucosal-Associated Invariant T Cell Deficiency in Systemic Lupus Erythematosus Is Realted to an Intrinsic Defect in the Ca2+/Calcineurin/NFAT1 Signaling Pathway
Yong-Wook Park¹, Young-Nan Cho², Hye-Mi Jin¹, Tae-Jong Kim³ and Seung-Jung Kee⁴, ¹Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Korea, Republic of (South), ²Rheumatology, Chonnam National University Hospital and Medical School, Gwangju, MN, Korea, Republic of (South), ³Chonnam Nat`l University Medical School&Hospital, Chonnam, Korea, Republic of (South), ⁴Laboratory Medicine, Chonnam National University Medical School and Hospital, Gwangju, Korea, Republic of (South)
Background/Purpose: Mucosal-associated invariant T (MAIT) cells contribute to protection against certain microorganism infections and play an important role in mucosal immunity. However, the role of…
Abstract Number: 1461 • 2017 ACR/ARHP Annual Meeting
The Relationship between Serum IL-37 and Disease Activity in Patients with Rheumatoid Arthritis: Post-Hoc Analysis of Planetra Study
Seoung Wan Nam¹, Hyuk Hee Kwon², Ga-Young Ahn³, Min Jung Kim² and Dae-Hyun Yoo¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ³Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)
The relationship between serum IL-37 and disease activity in patients with rheumatoid arthritis: post-hoc analysis of PLANETRA study. Background/Purpose: Rheumatoid Arthritis (RA) is a chronic…
Abstract Number: 1802 • 2017 ACR/ARHP Annual Meeting
Detection of Flare over the Past 3 Months in Rheumatoid Arthritis: Cross-Cultural Equivalence of the Self-Report Flare-RA Questionnaire
Francis Guillemin¹, Marie-Line Erpelding², Annette de Thurah^3,4,5,6, Elena Myasoedova⁷, Emilce E Schneeberger⁸, Cynthia S. Crowson⁹, Thomas Maribo¹⁰, Gustavo Citera¹¹, Eric L. Matteson¹² and Bruno Fautrel¹³, ¹University of Lorraine, Nancy, France, Nancy, France, ²CIC 1433 Clinical Epidemiology, Inserm, Nancy, France, ³Department of Rheumatology, Aarhus University Hospital, Århus C, Denmark, ⁴Department of Rheumatology, Aarhus University Hospital, Aarhus, DK, Aarhus, Denmark, ⁵Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, ⁶Department of Clinical Medicine, Aarhus University, Aarhus, DK, Aarhus N, Denmark, ⁷Rheumatology, Mayo Clinic, Rochester, MN, ⁸Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ⁹Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ¹⁰DEFACTUM, Central Region Denmark, Aarhus, Denmark, ¹¹Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ¹²Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, ¹³UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France
Background/Purpose: The Flare-RA questionnaire was developed and validated in French (1) for assessing the occurrence of a flare of rheumatoid arthritis (RA) during a 3-month…
Abstract Number: 2242 • 2017 ACR/ARHP Annual Meeting
Pattern and Influential Factors in Promoting Treat-to-Target (T2T) for Follow-up RA Patients with a Rheumatologist-Patient Interactive Smart System of Disease Management (SSDM): A Cohort Study from China
Rong Mu¹, Jing Yang², Hua Wei³, Wenqiang Fan⁴, Jianlin Huang⁵, Hongzhi Wang⁶, Jinli Ru⁷, Yongfu Wang⁸, Jinmei Zou², Jianling Dong², Xinwang Duan⁹, Fang He¹⁰, Xiaofei Shi¹¹, Xiafei Xin¹², Fei Xiao¹³, Hui Xiao¹³, Yuhua Jia¹³, Minjun Wang¹³, Lijun He¹³, Rui Bai¹³, Xiyao Huang¹³, Bing Wu¹³ and Zhanguo Li¹⁴, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Department of rheumatology, Central Hospital of MianYang, Sichuan, Mian Yang, China, ³No 98,Nantong West Rd,Yangzhou, Northern Jiangsu People's Hospital, Yangzhou, China, ⁴Department of rheumatology, Central Hospital of XinXiang, Henan, XinXiang, China, ⁵Department of rheumatology, The Sixth Hospital Affiliated to Sun yat-sen University, Guangzhou, China, ⁶The First Hospital of Jiaxing, Jiaxing, China, ⁷The 264th Hospital of the PLA, Taiyuan, China, ⁸The First Affiliated Hospital of BaoTou Medical College, Baotou, China, ⁹Department of rheumatology, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ¹⁰Central Hospital of Sui Ning, Sichuan, Suining, China, ¹¹The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China, ¹²Ningbo First Hospital, Zhejiang, Ningbo, China, ¹³Gothic Internet Technology Corporation, Shanghai, China, ¹⁴Rheum/Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: Treat-to-Target (T2T), achieving a DAS28 lower than 2.6 (remission) or below 3.2 (low disease activity), is the main management strategy. The Smart System of…
Abstract Number: 2521 • 2017 ACR/ARHP Annual Meeting
Metabolic Syndrome Is Associated with Active Disease in Psoriatic Arthritis and May Contribute to Development of Syndesmophytes
Pervin Sanci¹, Gokce Kenar², Berrin Zengin², Sadettin Uslu³, Aydan Koken³, Handan Yarkan³, Gerçek Can³, Merih Birlik³ and Fatos Onen², ¹Internal Medicine, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey, ²Rheumatology, Dokuz Eylul University Faculty of Medicine, Izmir, Turkey, ³Rheumatology, Dokuz Eylul University Faculty of Medicine, İzmir, Turkey
Background/Purpose: An increased prevalence of metabolic syndrome (MetS) has been reported in psoriatic arthritis (PsA) suggesting an association between the inflammation and MetS. The aim…
Abstract Number: 2903 • 2017 ACR/ARHP Annual Meeting
Serum CC-Chemokine Ligand 18 Level Is a Potential Biomarker of Disease Activity in IgG4-Related Disease
Mitsuhiro Akiyama¹, Hidekata Yasuoka², Keiko Yoshimoto² and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal Medicine,, Keio University School of Medicine, Tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic disorder characterized by severe fibrosis in lesions. In previous reports, CC-chemokine ligand 18 (CCL18) level is a substantial…
Abstract Number: 622 • 2017 ACR/ARHP Annual Meeting
Secukinumab Provides Sustained Minimal Disease Activity (MDA) and Remission Related to Disease Activity Index for Psoriatic Arthritis (DAPSA): 2-Year Results from a Phase 3 Study
Laura C Coates¹, Peter Nash², Tore Kvien³, Laure Gossec⁴, Philip J Mease⁵, Lawrence Rasouliyan⁶, Luminita Pricop⁷, Steffen Jugl⁸, Kunal Gandhi⁷, Corine Gaillez⁸ and Josef S. Smolen⁹, ¹University of Oxford, Leeds, Great Britain, ²University of Queensland, Brisbane, Australia, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴UPMC, University Paris 06, Pitié-Salpétrière Hospital, Paris, France, ⁵Swedish Medical Center and University of Washington, Seattle, WA, ⁶RTI Health Solutions, Barcelona, Spain, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria
Background/Purpose: Very low disease activity (VLDA) or remission (REM) and alternatively, minimal disease activity (MDA) or low disease activity (LDA) are optimal targets to be…
Abstract Number: 1078 • 2017 ACR/ARHP Annual Meeting
Initial Combination Therapy Versus Step-up Therapy Is More Effective and Less Costly As a Treat to Target Strategy for RA: A Markov Model Based upon the Dutch Rheumatoid Arthritis Monitoring Registry Cohorts
Celine J. van de Laar¹, Laura M.M. Steunebrink², Martijn A.H. Oude Voshaar³ and Harald E. Vonkeman⁴, ¹Transparency in Healthcare B.V., Hengelo, Netherlands, ²Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands, ³University of Twente, Department of Psychology, Health and Technology, Enschede, Netherlands, ⁴koningsplein, Medisch Spectrum Twente - Arthritis Center Twente, Enschede, Netherlands
Background/Purpose: Adjusting medication of patients with rheumatoid arthritis (RA) until predefined disease activity targets are met, i.e. Treat to Target (T2T), is the currently recommended…
Abstract Number: 1474 • 2017 ACR/ARHP Annual Meeting
A Higher DAS28P, the Subjective Proportion of the DAS28, Predicts a Favorable Response to Abatacept in Rheumatoid Arthritis
Jeong Seok Lee¹, HA Ahmad², Seung-Cheol Shim³, Sang-Cheol Bae⁴, Yeong Wook Song⁵ and Eun Young Lee⁶, ¹Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of (South), ²Bristol-Myers Squibb, Princeton, NJ, ³Division of Rheumatology, Department of Internal Medicine, Daejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon, Korea, Republic of (South), ⁴Department of Rhematology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁵WCU Department of Molecular Medicine and Biopharmaceutical Sciences, Medical Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of (South), ⁶Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
Background/Purpose: Response prediction of certain biologic agents for the treatment of rheumatoid arthritis (RA) is still an unmet need in real-world clinical practice. To reduce…
Abstract Number: 1806 • 2017 ACR/ARHP Annual Meeting
Performance of the Brief Index of Lupus Damage (BILD) in a Multi-Ethnic Population-Based Systemic Lupus Erythematosus (SLE) Cohort
Patricia P. Katz¹, Maria Dall'Era², Laura Trupin³, Stephanie Rush⁴, Charles G. Helmick⁵, Lindsey A. Criswell⁴ and Jinoos Yazdany³, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ⁴University of California, San Francisco, San Francisco, CA, ⁵Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: The BILD1,2 was developed and validated as a measure of SLE organ damage for use in epidemiologic studies in which administration of the SLICC…
Abstract Number: 2263 • 2017 ACR/ARHP Annual Meeting
Obesity Independently Associates with Worse Patient Reported Outcomes in Women with Systemic Lupus Erythematosus
Sarah L. Patterson¹, Gabriela Schmajuk², Kashif Jafri³, Katherine D. Wysham³ and Patricia P. Katz⁴, ¹Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA, ³University of California, San Francisco, San Francisco, CA, ⁴Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Obesity has been shown to exacerbate systemic inflammation in the general population and contributes to worse disease-related outcomes in rheumatoid arthritis. The impact of…
Abstract Number: 2531 • 2017 ACR/ARHP Annual Meeting
Utilization of the Psoriasis Epidemiology Screening Tool to Identify Signs and Symptoms of Early Psoriatic Arthritis Among Those with Psoriasis: Analysis from the Corrona Psoriasis Registry
Philip J Mease¹, Jacqueline B. Palmer², Mark Lebwohl³, Chitra Karki⁴, George W. Reed⁵, Carol J. Etzel⁶, Jeffrey D. Greenberg⁷ and Philip S. Helliwell⁸, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴Corrona, LLC, Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶The University of Texas MD Anderson Cancer Center, Houston, TX, ⁷New York University School of Medicine, New York, NY, ⁸School of Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: The Psoriasis Epidemiology Screening Tool (PEST) is a 5-item questionnaire developed to help identify psoriatic arthritis (PsA) at an early stage, with a score…
Abstract Number: 2907 • 2017 ACR/ARHP Annual Meeting
Salivary Gland Enlargement in IgG4-Related Disease Is Associated with Multiorgan Involvement and Higher Basal Disease Activity
Eduardo Martín Nares¹, Jacobo Guerrero Castillo², Arturo Angeles Angeles² and Gabriela Hernandez-Molina¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Department of Pathology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated condition which clinical spectrum encompasses single or multiple organ involvement. Enlargement of major and minor salivary glands is…
Abstract Number: 126 • 2017 ACR/ARHP Annual Meeting
Smoking Is Causally Associated with Disease Activity in Rheumatoid Arthritis
Milena Gianfrancesco¹, Laura Trupin², Stephen Shiboski³, Mark van der Laan⁴, Jonathan Graf⁵, John B. Imboden Jr.⁶, Jinoos Yazdany² and Gabriela Schmajuk⁷, ¹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ²Medicine/Rheumatology, University of California San Francisco, San Francisco, CA, ³Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, ⁴University of California, Berkeley, Berkeley, CA, ⁵Department of Medicine, Division of Rheumatology Zuckerberg San Francisco General Hospital, University of California, San Francisco, San Francisco, CA, ⁶Medicine, University of California, San Francisco, San Francisco, CA, ⁷San Francisco VA Medical Center, University of California San Francisco, San Francisco, CA
Background/Purpose: The association between smoking and risk of rheumatoid arthritis (RA) has been well documented; however, the relationship between smoking and RA disease activity is…
Abstract Number: 655 • 2017 ACR/ARHP Annual Meeting
Innate Lymphoid Cells – New Players in Psoriatic Arthritis
Alina Soare¹, Stefanie Weber², Lisa Maul³, Ana Maria Gheorghiu⁴, Ismail Housni⁵, Arnd Kleyer⁶, Markus Luber², Simon Rauber², David Simon⁶, Juergen Rech⁶, Georg Schett⁶, Jörg Distler¹ and Andreas Ramming⁷, ¹Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany, ²Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, ⁴Carol Davila University of Medicine and Pharmacy,Internal Medicine and Rheumatology Department ,,Dr.I.Cantacuzino'' Clinical Hospital, Bucharest, Romania, ⁵Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Erlangen, Germany, ⁶Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Erlangen, Germany., Erlangen, Germany, ⁷Department of Internal Medicine 3 – Rheumatology and Immunology, Universitätsklinikum Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany
Background/Purpose: Innate lymphoid cells (ILCs) produce disease-related cytokines including IL-17 and IL-22 and are therefore of substantial interest in PsA. Spreading the disease from the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].